Literature DB >> 28284323

Optimizing drug delivery in COPD: The role of inhaler devices.

Paola Rogliani1, Luigino Calzetta2, Angelo Coppola2, Francesco Cavalli2, Josuel Ora2, Ermanno Puxeddu2, Maria Gabriella Matera3, Mario Cazzola2.   

Abstract

BACKGROUND: Inhaled medication is the cornerstone of the pharmacological treatment for patients with asthma and chronic obstructive pulmonary disease (COPD). Several inhaler devices exist, and each device has specific characteristics to achieve the optimal inhalation of drugs. The correct use of inhaler devices is not granted and patients may incur in mistakes when using pressurized metered-dose inhalers (pMDIs) or dry-powder inhaler (DPIs). The incorrect use of inhaler devices can lead to a poorly controlled disease status. Unfortunately, guidelines provide limited guidance regarding the choice of devices. This article presents a review of the literature on different inhaler device requirements. Data from literature (PubMed and Google Scholar) on the commercially available inhaler devices have been evaluated and the history of inhaler medicine described. Furthermore, advantages and disadvantages of each type of device have been analyzed. The evaluation of literature indicated the availability of robust data on the devices characteristics and factors influencing selection of delivery devices. Each type of device has its own pro and cons. The age, cognitive status, visual acuity, manual dexterity, manual strength and ability to coordinate the inhaler actuation with inhalation may be as important as the disease severity in determining the correct approach to delivery of respiratory medication. The administration of effective therapies via a device that is simple to use and accepted by patients may help to improve treatment outcomes in patients with COPD.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asthma; COPD; Inhaler device

Mesh:

Substances:

Year:  2017        PMID: 28284323     DOI: 10.1016/j.rmed.2017.01.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  29 in total

Review 1.  Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF).

Authors:  Valentina Sala; Jean Piero Margaria; Alessandra Murabito; Fulvio Morello; Alessandra Ghigo; Emilio Hirsch
Journal:  Curr Heart Fail Rep       Date:  2017-06

Review 2.  Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.

Authors:  Shohreh Alipour; Laleh Mahmoudi; Fatemeh Ahmadi
Journal:  Drug Deliv Transl Res       Date:  2022-10-19       Impact factor: 5.671

3.  Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.

Authors:  Paola Rogliani; Maria Gabriella Matera; Francesco Facciolo; Clive Page; Mario Cazzola; Luigino Calzetta
Journal:  Br J Pharmacol       Date:  2020-01-29       Impact factor: 8.739

Review 4.  The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis.

Authors:  Paola Rogliani; Maria Gabriella Matera; Josuel Ora; Mario Cazzola; Luigino Calzetta
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-12-05

Review 5.  Doxofylline is not just another theophylline!

Authors:  Maria Gabriella Matera; Clive Page; Mario Cazzola
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-12-05

6.  Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.

Authors:  Luigino Calzetta; Maria Gabriella Matera; Francesco Facciolo; Mario Cazzola; Paola Rogliani
Journal:  Respir Res       Date:  2018-04-12

7.  Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology.

Authors:  Pei-Yao Xu; Ranjith Kumar Kankala; Yu-Jing Pan; Hui Yuan; Shi-Bin Wang; Ai-Zheng Chen
Journal:  Int J Nanomedicine       Date:  2018-08-15

8.  Physiological predictors Of peak inspiRatory flow using Observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation.

Authors:  David B Price; Sen Yang; Simon Wan Yau Ming; Antony Hardjojo; Claudia Cabrera; Andriana I Papaioannou; Stelios Loukides; Vicky Kritikos; Sinthia Z Bosnic-Anticevich; Victoria Carter; Paul M Dorinsky
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-12-13

9.  LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.

Authors:  Paola Rogliani; Luigino Calzetta; Fulvio Braido; Mario Cazzola; Enrico Clini; Girolamo Pelaia; Andrea Rossi; Nicola Scichilone; Fabiano Di Marco
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-04

10.  Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow® CS.

Authors:  Judith J Stephenson; Carole Dembek; Amanda Caldwell-Tarr; Rebecca M Conto; Mark Paullin; Edward M Kerwin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.